R. H. Hruban

This paper develops a multimodal prognostic model for pancreatic neuroendocrine tumors using clinicopathologic data and histology images, finding that stromal features are as prognostic as tumor cells.

The paper identifies genomically stable regions in metastatic pancreatic cancer that can be targeted by CRISPR-Cas9 due to preserved PAM sites, suggesting a potential gene therapy approach.

This study shows that 3D assessments are necessary to accurately determine tissue composition and neoplastic content, as 2D methods under-sample spatial heterogeneity.

The paper uses AI-based 3D tissue mapping to show PanIN lesion sizes follow a power-law distribution and identifies growth mechanisms driving pancreatic cancer precursor lesions.

This paper demonstrates CRISPR-Cas9 can selectively target somatic mutations in pancreatic cancer by exploiting PAMs in noncoding regions, achieving >80% cell death with minimal off-target effects.

This study shows CRISPR-Cas9-induced DNA double-strand breaks are more cytotoxic to pancreatic cancer cells than radiation-induced breaks, with significant tumor growth inhibition and chromosomal instability.

The paper develops a method to spatially quantify mitochondrial DNA copy number in cancer tissues and finds increased mtDNAcn in prostate cancer progression, linked to MYC activity.

This study uses 3D imaging and genomic analysis to show that human pancreatic precancerous lesions (PanINs) are highly multifocal and genetically heterogeneous.

The paper develops a method to reconstruct 3D pancreatic tissue at single-cell resolution and maps cancer invasion modes in the tumor microenvironment.

This study develops tumor-specific antibodies for early detection of pancreatic cancer using PET imaging in mouse models, identifying two mAbs that bind to CEACAM6 variants in tumors.

This paper introduces a label-free volumetric imaging technique for thick-tissue slides with subcellular resolution, demonstrating its ability to visualize various tumor types and pathologies.

This study identifies genetic features of recurrent pancreatic cancer through sequencing and finds that treatment-induced genetic changes and potential second primary tumors influence recurrence.

The paper describes a PCR-based assay for detecting aneuploidy in low DNA samples, showing 49% prevalence in non-metastatic cancers and 80% sensitivity when combined with other biomarkers.

The paper identifies genetic and transcriptional features of basal-like subtypes in pancreatic ductal adenocarcinoma, linking them to squamous histology and chromatin modifier mutations.